Screener
Collegium Pharmaceutical, Inc. COLL Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $199.88M+6.3% | $193.52M+8.9% | $205.45M+12.9% | $209.36M+31.4% | $188M+29.4% | ||
| $89.59M+12.5% | $76.27M-5.2% | $77.07M-7.9% | $80.19M+28.3% | $79.62M+46.2% | ||
| $110.29M+1.8% | $117.25M+20.5% | $128.38M+30.6% | $129.17M+33.4% | $108.38M+19.4% | ||
| 55.2%-2.5pp | 60.6%+5.8pp | 62.5%+8.5pp | 61.7%+0.9pp | 57.7%-4.9pp | ||
| $106.59M+44.8% | $86.35M+13.0% | $67.64M+7.2% | $67.1M+8.3% | $73.64M+69.9% | ||
| $106.59M+45.5% | $86.35M+14.2% | $67.62M+12.4% | $67.08M+8.3% | $73.28M+69.1% | ||
| $3.7M-89.5% | $30.9M+42.5% | $60.76M+59.4% | $62.09M+78.2% | $35.11M-26.0% | ||
| 1.9%-16.8pp | 16%+3.8pp | 29.6%+8.6pp | 29.7%+7.8pp | 18.7%-14.0pp | ||
| $19.52M-4.6% | $15.86M-23.7% | $19.29M-14.8% | $21.77M+18.3% | $20.46M+31.3% | ||
| -$13.53M-179% | $18.74M+500% | $29.04M+68.1% | $43.44M+179% | $17.03M-41.5% | ||
| $1.52M-69.9% | $4.24M+502% | $12.07M+155% | $11.93M+91.0% | $5.04M-46.9% | ||
| -$15.05M-226% | $14.5M+500% | $16.96M+35.3% | $31.51M+238% | $11.98M-38.9% | ||
| -7.5%-13.9pp | 7.5%+6.1pp | 8.3%+1.4pp | 15%+9.2pp | 6.4%-7.1pp | ||
| -$0.46-235% | $0.40+471% | $0.46+27.8% | $0.84+211% | $0.34-34.6% | ||
| $68.46M-25.4% | $86.83M+11.0% | $61.68M-34.8% | $63.12M-17.6% | $91.71M+10.6% | ||
| 34.3%-14.5pp | 44.9%+0.8pp | 30%-22.0pp | 30.1%-17.9pp | 48.8%-8.3pp | ||
| $3.7M-89.5% | $30.9M+42.5% | $60.76M+59.4% | $62.09M+78.2% | $35.11M-26.0% |
FAQ
- What is Collegium Pharmaceutical, Inc.'s revenue?
- Collegium Pharmaceutical, Inc. (COLL) generated $808.2M in revenue over the trailing twelve months, up 14.3% year over year.
- Is Collegium Pharmaceutical, Inc. profitable?
- Collegium Pharmaceutical, Inc. reported $47.9M in net income over the trailing twelve months, a 5.9% net margin.
- What are Collegium Pharmaceutical, Inc.'s profit margins?
- Gross margin is 60.0% and operating margin is 19.5%, with a 5.9% net margin.
- What is Collegium Pharmaceutical, Inc.'s earnings per share?
- Collegium Pharmaceutical, Inc.'s diluted EPS over the trailing twelve months is $1.24.
- Where does Collegium Pharmaceutical, Inc.'s income statement data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
